A Phase 3 Trial of Bardoxolone Methyl in Patients With Autosomal Dominant Polycystic Kidney Disease
Phase of Trial: Phase III
Latest Information Update: 21 Oct 2019
Price : $35 *
At a glance
- Drugs Bardoxolone methyl (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms FALCON
- Sponsors Reata Pharmaceuticals
- 30 May 2019 Status changed from not yet recruiting to recruiting.
- 30 May 2019 According to a Reata Pharmaceuticals media release, first patient has been enrolled.
- 09 May 2019 According to a Reata Pharmaceuticals media release, the company expects to enroll first patient in this trial in May 2019.